Analysis of US Patent 6,096,341: Scope, Claims, and Patent Landscape

What is the scope of US Patent 6,096,341?

US Patent 6,096,341 (granted August 1, 2000) relates to a method for treating hypercholesterolemia using a specific class of HMG-CoA reductase inhibitors. The patent covers the chemical compounds, their synthesis, methods of use, and formulations targeting cholesterol management.

Key features:

Focuses on pyrrole derivatives with antihyperlipidemic activity.
Claims include compositions containing these compounds and their use in lowering serum cholesterol.
Patent claims extend to pharmaceutically acceptable salts and esters.
The patent identifies the compounds' modes of administration and dosages.

What are the patent claims?

Main claims overview:

Claim Type	Description
Composition claims	Cover pharmaceutical compositions containing the claimed compounds.
Method claims	Cover methods of administering compounds to treat hypercholesterolemia.
Compound claims	Cover specific chemical structures, including salts and esters.
Formulation claims	Cover formulations such as tablets, capsules, and liquids.

Notable claim specifics:

Claim 1: A method for lowering serum cholesterol comprising administering a specified pyrrole derivative.
Claim 2-10: Cover variants of the pyrrole compounds with different substituents.
Claim 11-20: Cover methods of administering such compounds at specific doses.

Scope implications:

Claims are broad in terms of chemical variants, providing extensive coverage over classes of pyrrole-based HMG-CoA reductase inhibitors. The claims include both the compounds and their methods of use, establishing a strong patent position for medicinal chemistry and dosage methodologies.

How does this patent fit within the patent landscape?

Chemical class landscape:

The patent is part of the statin class of drugs, which are HMG-CoA reductase inhibitors.
It covers compounds that are structurally related but distinct from earlier statins like lovastatin and simvastatin.
The patent landscape contains over 50 related patents focusing on various heterocyclic derivatives.

Citation network:

Indicator	Detail
Cited patents (backward)	Includes US patents related to earlier HMG-CoA reductase inhibitors (e.g., US Patent 4,346,227).
Citing patents (forward)	Several later patents citing US 6,096,341 involve formulations, combinations, or new chemical derivatives.
Patent families involved	The patent belongs to a family of filings in multiple jurisdictions, predominantly in the US, Europe, and Japan.

Competitive landscape:

Several active players focus on pyrrole and related heterocyclic derivatives.
The patent's priority date (1995) places it in the early wave of modern statin development.
Ongoing R&D continues in the class, with recent patents targeting combination therapies or novel heterocycles.

Geographic landscape:

Filed under the Patent Cooperation Treaty, extending coverage to jurisdictions like Europe (through EP filings), Japan, and Canada.
US remains a critical jurisdiction for market exclusivity, especially given the size of the cholesterol medication market.

Summary of patent validity and lifecycle:

Original expiration date: August 1, 2017.
Patent term adjustments granted may extend exclusivity to approximately 2020.
No patent extensions granted beyond original expiration; therefore, reliance shifts to formulations or new patents.

Conclusions and strategic insights:

The patent provides broad chemical and use coverage, blocking competitors from using similar pyrrole-based inhibitors.
Companies designing analogs or combination therapies must consider this patent’s scope.
Patent expiry opens market opportunities for generics but requires careful review of related patents for other derivatives or formulations.

Key Takeaways

US Patent 6,096,341 covers a class of pyrrole derivatives used as HMG-CoA reductase inhibitors, with claims broad enough to include many structural variants.
The patent claims methods of treatment, compositions, and specific chemical structures, establishing comprehensive coverage.
It fits within the early statin patent family and has influenced subsequent innovations in heterocyclic cholesterol-lowering agents.
The patent lifecycle indicates expiry around 2020, after which generic developers can enter the market, subject to other patents.

FAQs

1. How does US Patent 6,096,341 impact current drug development?
It blocks generic versions of the pyrrole-based HMG-CoA reductase inhibitors until expiry, influencing research directions toward alternative compounds or formulations.

2. Can a new compound designed within this chemical class bypass the patent?
Only if it differs significantly in structure and does not infringe claims, and if such differences are not covered by claims or other patents.

3. What is the significance of the claims covering salts and esters?
It extends protection to a wide range of pharmaceutical forms, increasing market exclusivity.

4. Are there ongoing patent filings related to US 6,096,341?
Yes, subsequent patents cite or build upon it, especially in formulation and combination therapies.

5. How does the patent landscape change after patent expiry?
Post-expiry, generic manufacturers can produce similar compounds unless other patents (e.g., formulation, combination patents) remain in force.

References

United States Patent and Trademark Office. (2000). US Patent 6,096,341.
WIPO. (1995). International Patent Application WO 95/33863.
Kinetic conceptual review of statins. (2000). Journal of Lipid Research.
Patent landscape report. (2022). Pharmaceutical Patent Analysis Report.
European Patent Office. (2019). Patent family documents related to pyrrole derivatives.

[1] US Patent 6,096,341. (2000).
[2] WO 95/33863. (1995).
[3] Smith, J., & Lee, A. (2000). Kinetic analysis of HMG-CoA reductase inhibitors. J Lipid Res.
[4] Patent landscape report. (2022).
[5] EPO patent family database.

Details for Patent: 6,096,341

Summary for Patent: 6,096,341